Investor Backing & Capital Strength:
A seed round in 2024 and a related securities filing indicate access to meaningful capital to fund product and go‑to‑market. Multiple profiles consistently reference mid‑eight‑figure early financing tied to the Medbill AI → Granted transition.
Strategic Partnerships:
A March 2026 partnership with StretchDollar expands distribution into employer benefits channels. Such channel additions broaden reach beyond direct‑to‑consumer acquisition.
Innovation-Driven Growth:
The iOS app launched publicly in late 2024 and has been updated regularly through early 2026, alongside a rebrand from Medbill AI to Granted. These moves signal active iteration and an expanding product scope.
